RedHill Biopharma Ltd.RDHLEarnings & Financial Report
RedHill Biopharma Ltd. is a specialty biopharmaceutical firm focused on developing and commercializing innovative therapeutics for gastrointestinal disorders, inflammatory conditions, and infectious diseases. It operates mainly in North American and European markets, delivering prescription treatments for unmet clinical needs and partnering with healthcare stakeholders to expand product access.
RDHL Q2 FY2022 Key Financial Metrics
Revenue
$18.3M
Gross Profit
$9.4M
Operating Profit
$-9.2M
Net Profit
$-11.7M
Gross Margin
51.0%
Operating Margin
-49.9%
Net Margin
-63.8%
YoY Growth
-14.7%
EPS
$-0.02
RedHill Biopharma Ltd. Q2 FY2022 Financial Summary
RedHill Biopharma Ltd. reported revenue of $18.3M (down 14.7% YoY) for Q2 FY2022, with a net profit of $-11.7M (up 59.8% YoY) (-63.8% margin). Cost of goods sold was $9.0M, operating expenses totaled $18.5M.
Key Financial Metrics
| Total Revenue | $18.3M |
|---|---|
| Net Profit | $-11.7M |
| Gross Margin | 51.0% |
| Operating Margin | -49.9% |
| Report Period | Q2 FY2022 |
Income Statement
| Q2 2022 | |
|---|---|
| Revenue | $18.3M |
| YoY Growth | -14.7% |
Balance Sheet
| Q2 2022 | |
|---|---|
| Assets | $168.0M |
| Liabilities | $179.9M |
| Equity | $-11.9M |
Cash Flow
| Q2 2022 | |
|---|---|
| Operating CF | $-16.6M |